Physician profile
Chan Park
NPI 1255336665
$3,679.12
in general payments reported to CMS, 2019-2025
26 companies · $743 in 2025
The $743 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $480 · 2020: $533 · 2021: $430 · 2022: $409 · 2023: $476 · 2024: $608 · 2025: $743.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,827.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,826.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $617.81 | 2019-2025 | Gardasil 9, Verquvo, Vaxneuvance |
| Lilly USA, LLC | $531.91 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $458.30 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $427.70 | 2019-2024 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $405.15 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $294.39 | 2019-2025 | Jardiance, Synjardy |
| Abbvie INC. | $194.99 | 2022-2025 | |
| Medtronic Vascular, INC. | $167.80 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $83.32 | 2021-2024 | |
| Amgen INC. | $77.13 | 2020-2025 | Otezla, Repatha, Otezla |
| Novartis Pharmaceuticals Corporation | $62.89 | 2021-2022 | |
| Corcept Therapeutics | $45.50 | 2025 | Korlym |
| Exact Sciences Corporation | $39.70 | 2024-2025 | Cologuard Collection Kit |
| Medtronic, INC. | $36.69 | 2025 | Symplicity G3 |
| Kowa Pharmaceuticals America, INC. | $32.68 | 2025 | Zoryve |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $30.39 | 2024 | Trelegy Ellipta, Arexvy |
| Abiomed | $24.05 | 2025 | |
| Sanofi Pasteur INC. | $21.75 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.50 | 2025 | Xifaxan |
| Abbott Laboratories | $20.17 | 2025 | Freestyle Libre 3 |
| Sarepta Therapeutics, INC. | $17.42 | 2021 | |
| Allergan, INC. | $17.17 | 2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.78 | 2024 | Caplyta |
| Dexcom, INC. | $14.62 | 2022 | |
| Janssen Pharmaceuticals, INC | $14.44 | 2019 | |
| Phathom Pharmaceuticals, INC. | $6.87 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chan Park listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.